{
    "info": {
        "nct_id": "NCT04207255",
        "official_title": "A Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients With Prostate Cancer Progression on Enzalutamide or Abiraterone",
        "inclusion_criteria": "1. Patient must have mCRPC. Each patient must have:\n\n   * Tissue diagnosis documented by pathology report, or clinic note attesting to same.\n   * Radiographically-demonstrated metastases\n   * Patients must have adenocarcinoma, or ductal carcinoma, or combinations of these two entities\n2. Voluntary, signed and dated, institutional review board (IRB)-approved informed consent form in accordance with regulatory and institutional guidelines.\n3. Documented progression during treatment with enzalutamide or abiraterone, as determined by the enrolling investigator.\n4. Testosterone level documented to be less than 50ng/\n5. 18 years of age or older.\n6. ECOG performance status of 0-2.\n7. Acceptable liver function:\n\n   * Bilirubin ≤ 1.5 times upper limit of normal (CTCAE Grade 1 baseline)\n   * AST (SGOT) & ALT (SGPT) ≤ 3 x ULN (CTCAE Grade 1 baseline)\n   * Subjects with Gilbert's syndrome may be included if the total bilirubin is <3x ULN and the direct bilirubin is within normal limits\n8. Acceptable kidney function indicated by serum creatinine ≤ 1.5 X ULN (CTCAE Grade 1 baseline)\n9. Acceptable hematologic status:\n\n   * Absolute neutrophil count ≥ 1000 cells/mm3,\n   * Platelet count ≥ 75,000 (plt/mm3) (CTCAE Grade 1 baseline)\n   * Hemoglobin ≥ 9.0 g/dL.\n10. Fasting blood glucose of <165mg/dL\n11. Urinalysis: no clinically significant abnormalities\n12. International normalized ratio (INR) ≤1.7\n13. Well-controlled blood pressure as determined by the treating investigator\n14. Patients requiring narcotic analgesics must be on stable doses for at least 2 weeks prior to study entry.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG.\n2. Underlying psychiatric disorder requiring hospitalization within the last two years.\n3. Clinically significant neurological disorder (Parkinson's disease, dementia, multiple sclerosis), as determined by the enrolling investigator.\n4. Active, uncontrolled bacterial, viral or fungal infection, requiring systemic therapy.\n5. Treatment with radiation therapy, surgery, or investigational therapy within 28 days prior to registration.\n6. Unwillingness or inability to comply with procedures required in this protocol.\n7. Serious nonmalignant disease that could compromise protocol objectives in the opinion of the Investigator.\n8. Patients who are receiving coumadin, apixaban, argatroban or rivaroxaban. Patients who are receiving other drugs that are sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or inducers of all major CYP450 isozymes that cannot be stopped at least 7 days or 5 half-lives (whichever is longer) before starting treatment with opaganib may be treated on this study with careful monitoring for toxic effects or loss of efficacy of the relevant drug. A list of commonly used drugs that are sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or inducers of all major CYP450 isozymes with the half-life of each drug identified, is included as an Appendix C.\n9. Patients who are currently participating in any other clinical trial of an investigational product.\n10. Other primary malignancy requiring systemic treatment within past 5 years except carcinoma in situ of the cervix or urinary bladder or non-melanoma skin cancer.\n11. Any other mental incapacitation or psychiatric illness that would preclude study participation, as determined by the enrolling investigator.\n12. Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "1. Patient must have mCRPC. Each patient must have:",
            "criterions": [
                {
                    "exact_snippets": "Patient must have mCRPC",
                    "criterion": "mCRPC (metastatic castration-resistant prostate cancer)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tissue diagnosis documented by pathology report, or clinic note attesting to same.",
            "criterions": [
                {
                    "exact_snippets": "Tissue diagnosis documented by pathology report",
                    "criterion": "tissue diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": "pathology report"
                        }
                    ]
                },
                {
                    "exact_snippets": "clinic note attesting to same",
                    "criterion": "tissue diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": "clinic note attestation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiographically-demonstrated metastases",
            "criterions": [
                {
                    "exact_snippets": "Radiographically-demonstrated metastases",
                    "criterion": "metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "demonstration_method",
                            "expected_value": "radiographically"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have adenocarcinoma, or ductal carcinoma, or combinations of these two entities",
            "criterions": [
                {
                    "exact_snippets": "Patients must have adenocarcinoma, or ductal carcinoma, or combinations of these two entities",
                    "criterion": "cancer histology",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "adenocarcinoma",
                                "ductal carcinoma",
                                "combinations of these two entities"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Voluntary, signed and dated, institutional review board (IRB)-approved informed consent form in accordance with regulatory and institutional guidelines.",
            "criterions": [
                {
                    "exact_snippets": "Voluntary, signed and dated, institutional review board (IRB)-approved informed consent form",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "voluntariness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dated",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "IRB approval",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in accordance with regulatory and institutional guidelines",
                    "criterion": "informed consent process",
                    "requirements": [
                        {
                            "requirement_type": "compliance with regulatory and institutional guidelines",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Testosterone level documented to be less than 50ng/",
            "criterions": [
                {
                    "exact_snippets": "Testosterone level documented to be less than 50ng/",
                    "criterion": "testosterone level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Documented progression during treatment with enzalutamide or abiraterone, as determined by the enrolling investigator.",
            "criterions": [
                {
                    "exact_snippets": "Documented progression during treatment with enzalutamide or abiraterone",
                    "criterion": "disease progression during treatment with enzalutamide or abiraterone",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during treatment with enzalutamide or abiraterone"
                        }
                    ]
                },
                {
                    "exact_snippets": "as determined by the enrolling investigator",
                    "criterion": "progression determination by enrolling investigator",
                    "requirements": [
                        {
                            "requirement_type": "determination",
                            "expected_value": "enrolling investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. 18 years of age or older.",
            "criterions": [
                {
                    "exact_snippets": "18 years of age or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. ECOG performance status of 0-2.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Acceptable liver function:",
            "criterions": [
                {
                    "exact_snippets": "Acceptable liver function",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin ≤ 1.5 times upper limit of normal (CTCAE Grade 1 baseline)",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin ≤ 1.5 times upper limit of normal (CTCAE Grade 1 baseline)",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST (SGOT) & ALT (SGPT) ≤ 3 x ULN (CTCAE Grade 1 baseline)",
            "criterions": [
                {
                    "exact_snippets": "AST (SGOT) ... ≤ 3 x ULN",
                    "criterion": "AST (SGOT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT (SGPT) ... ≤ 3 x ULN",
                    "criterion": "ALT (SGPT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with Gilbert's syndrome may be included if the total bilirubin is <3x ULN and the direct bilirubin is within normal limits",
            "criterions": [
                {
                    "exact_snippets": "Subjects with Gilbert's syndrome may be included",
                    "criterion": "Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin is <3x ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin is within normal limits",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within normal limits"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Acceptable kidney function indicated by serum creatinine ≤ 1.5 X ULN (CTCAE Grade 1 baseline)",
            "criterions": [
                {
                    "exact_snippets": "serum creatinine ≤ 1.5 X ULN (CTCAE Grade 1 baseline)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Acceptable hematologic status:",
            "criterions": [
                {
                    "exact_snippets": "Acceptable hematologic status",
                    "criterion": "hematologic status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count ≥ 1000 cells/mm3,",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count ≥ 1000 cells/mm3",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "cells/mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count ≥ 75,000 (plt/mm3) (CTCAE Grade 1 baseline)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 75,000 (plt/mm3)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "plt/mm3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "CTCAE Grade 1 baseline",
                    "criterion": "platelet count CTCAE grade at baseline",
                    "requirements": [
                        {
                            "requirement_type": "CTCAE grade at baseline",
                            "expected_value": "1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Fasting blood glucose of <165mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Fasting blood glucose of <165mg/dL",
                    "criterion": "fasting blood glucose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 165,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥ 9.0 g/dL.",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Urinalysis: no clinically significant abnormalities",
            "criterions": [
                {
                    "exact_snippets": "Urinalysis: no clinically significant abnormalities",
                    "criterion": "urinalysis",
                    "requirements": [
                        {
                            "requirement_type": "abnormalities",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "clinical_significance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Well-controlled blood pressure as determined by the treating investigator",
            "criterions": [
                {
                    "exact_snippets": "Well-controlled blood pressure as determined by the treating investigator",
                    "criterion": "blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "well-controlled"
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "as determined by the treating investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. International normalized ratio (INR) ≤1.7",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) ≤1.7",
                    "criterion": "international normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.7,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Patients requiring narcotic analgesics must be on stable doses for at least 2 weeks prior to study entry.",
            "criterions": [
                {
                    "exact_snippets": "Patients requiring narcotic analgesics must be on stable doses for at least 2 weeks prior to study entry.",
                    "criterion": "narcotic analgesic use",
                    "requirements": [
                        {
                            "requirement_type": "dose stability",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "2. Underlying psychiatric disorder requiring hospitalization within the last two years.",
            "criterions": [
                {
                    "exact_snippets": "Underlying psychiatric disorder requiring hospitalization within the last two years",
                    "criterion": "psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hospitalization_required",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Patients who are currently participating in any other clinical trial of an investigational product.",
            "criterions": [
                {
                    "exact_snippets": "currently participating in any other clinical trial of an investigational product",
                    "criterion": "participation in other clinical trial of an investigational product",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Clinically significant neurological disorder (Parkinson's disease, dementia, multiple sclerosis), as determined by the enrolling investigator.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant neurological disorder (Parkinson's disease, dementia, multiple sclerosis)",
                    "criterion": "neurological disorder",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "examples",
                            "expected_value": [
                                "Parkinson's disease",
                                "dementia",
                                "multiple sclerosis"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "as determined by the enrolling investigator",
                    "criterion": "neurological disorder assessment",
                    "requirements": [
                        {
                            "requirement_type": "assessment authority",
                            "expected_value": "enrolling investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Unwillingness or inability to comply with procedures required in this protocol.",
            "criterions": [
                {
                    "exact_snippets": "Unwillingness ... to comply with procedures required in this protocol",
                    "criterion": "willingness to comply with protocol procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inability to comply with procedures required in this protocol",
                    "criterion": "ability to comply with protocol procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Treatment with radiation therapy, surgery, or investigational therapy within 28 days prior to registration.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with radiation therapy ... within 28 days prior to registration.",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... surgery ... within 28 days prior to registration.",
                    "criterion": "surgery",
                    "requirements": [
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... investigational therapy within 28 days prior to registration.",
                    "criterion": "investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Serious nonmalignant disease that could compromise protocol objectives in the opinion of the Investigator.",
            "criterions": [
                {
                    "exact_snippets": "Serious nonmalignant disease that could compromise protocol objectives",
                    "criterion": "serious nonmalignant disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "potential to compromise protocol objectives",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the Investigator",
                    "criterion": "Investigator opinion",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "Investigator's judgment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Any other mental incapacitation or psychiatric illness that would preclude study participation, as determined by the enrolling investigator.",
            "criterions": [
                {
                    "exact_snippets": "Any other mental incapacitation or psychiatric illness that would preclude study participation, as determined by the enrolling investigator.",
                    "criterion": "mental incapacitation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "impact on study participation",
                            "expected_value": "would preclude study participation"
                        },
                        {
                            "requirement_type": "determination",
                            "expected_value": "as determined by the enrolling investigator"
                        }
                    ]
                },
                {
                    "exact_snippets": "Any other mental incapacitation or psychiatric illness that would preclude study participation, as determined by the enrolling investigator.",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "impact on study participation",
                            "expected_value": "would preclude study participation"
                        },
                        {
                            "requirement_type": "determination",
                            "expected_value": "as determined by the enrolling investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.",
            "criterions": [
                {
                    "exact_snippets": "Prisoners",
                    "criterion": "prisoner status",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness",
                    "criterion": "compulsory detention for treatment",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG.",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association Class III or IV",
                    "criterion": "New York Heart Association (NYHA) class",
                    "requirements": [
                        {
                            "requirement_type": "classification",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction within the past 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable arrhythmia",
                    "criterion": "unstable arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of ischemia on ECG",
                    "criterion": "ischemia on ECG",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Active, uncontrolled bacterial, viral or fungal infection, requiring systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Active, uncontrolled bacterial ... infection, requiring systemic therapy.",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active, uncontrolled ... viral ... infection, requiring systemic therapy.",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active, uncontrolled ... fungal infection, requiring systemic therapy.",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Patients who are receiving coumadin, apixaban, argatroban or rivaroxaban. Patients who are receiving other drugs that are sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or inducers of all major CYP450 isozymes that cannot be stopped at least 7 days or 5 half-lives (whichever is longer) before starting treatment with opaganib may be treated on this study with careful monitoring for toxic effects or loss of efficacy of the relevant drug. A list of commonly used drugs that are sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or inducers of all major CYP450 isozymes with the half-life of each drug identified, is included as an Appendix C.",
            "criterions": [
                {
                    "exact_snippets": "Patients who are receiving coumadin, apixaban, argatroban or rivaroxaban",
                    "criterion": "use of specific anticoagulant drugs",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": [
                                "coumadin",
                                "apixaban",
                                "argatroban",
                                "rivaroxaban"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who are receiving other drugs that are sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or inducers of all major CYP450 isozymes that cannot be stopped at least 7 days or 5 half-lives (whichever is longer) before starting treatment with opaganib",
                    "criterion": "use of drugs that are sensitive substrates, strong inhibitors, or inducers of major CYP450 isozymes",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": "drugs that are sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or inducers of all major CYP450 isozymes"
                        },
                        {
                            "requirement_type": "ability to discontinue",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "ability to discontinue",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "half-lives"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Other primary malignancy requiring systemic treatment within past 5 years except carcinoma in situ of the cervix or urinary bladder or non-melanoma skin cancer.",
            "criterions": [
                {
                    "exact_snippets": "Other primary malignancy requiring systemic treatment within past 5 years",
                    "criterion": "other primary malignancy",
                    "requirements": [
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except carcinoma in situ of the cervix or urinary bladder or non-melanoma skin cancer",
                    "criterion": "carcinoma in situ of the cervix or urinary bladder or non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}